
The FDA has approved the use of osimertinib, a third-generation EGFR tyrosine kinase inhibitor, for the treatment of locally advanced, unresectable non-small cell lung cancer in certain adult patients.


coremsg

Approval follows priority review granted based on findings from the LAURA trial.

FDA Approves Osimertinib for Unresectable NSCLC

fda-approves-osimertinib-a-third-generation-egfr-tyrosine-kinase-inhibitor-for-unresectable-non-small-cell-lung-cancer


FDA Approves Osimertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, for Unresectable Non-Small Cell Lung Cancer
